Section Arrow
CLDI.NYSE-M
- Calidi Biotherapeutics
Quotes are at least 15-min delayed:2025/07/21 06:57 EDT
Pre Market
Last
 0.5817
-0.0119 (-2.00%)
Bid
0.5813
Ask
0.5936
High 0.5947 
Low 0.5501 
Volume 10147 
Regular Hours
Last
 0.5936
-0.0223 (-3.62%)
Day High 
0.6432 
Prev. Close
0.6159 
1-M High
1.6 
Volume 
2.57M 
Bid
0.5813
Ask
0.5936
Day Low
0.5695 
Open
0.6029 
1-M Low
0.2027 
Market Cap 
21.26M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.57 
20-SMA 0.41 
50-SMA 0.39 
52-W High 3.89 
52-W Low 0.2027 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-1.12/-8.80
Enterprise Value
23.85M
Balance Sheet
Book Value Per Share
0.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.97 -0.31 -13.60%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13 -1.075 -7.64%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.23 +0.39 +6.68%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.11 +0.19 +3.21%
Quotes are at least 15-min delayed:2025/07/21 06:57 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.